Given Imaging Announces 85 Capsule Endoscopy Studies to Be Presented at Digestive Disease Week 2005

Given Imaging (Nasdaq: GIVN - News) announced today that 85 abstracts on capsule endoscopy will be presented at this year's Digestive Disease Week® 2005 (DDW®) in Chicago May 14 - 19 at McCormick Place. Given Imaging will host booth number 1024.

"Since launching the PillCam platform four years ago we have established a large footprint in the field of G.l. diagnostics and the number of studies presented this year confirms PillCam's use as a primary diagnostic tool for an ever increasing list of indications," said Gavriel D. Meron, president and chief executive officer of Given Imaging. "The data also indicates that PillCam SB is clearly the gold standard for mucosal imaging of the entire small bowel and that our newest capsule endoscope, PillCam ESO, presents a tremendous opportunity for less invasive imaging of the esophagus."


Clinical data studies to be presented on capsule endoscopy include:

Celiac Disease

* "Evaluation of capsule Endoscopy in Celiac disease Patients with
Ongoing symptoms on a Gluten-Free Diet- A prospective Blinded European
Multicenter trial" (Presentation 547) - Tuesday, May 17th at 2:30pm -
2:45pm, McCormick Place - E450A

* "Video Capsule Endoscopy for the Diagnosis of Celiac Disease:
Preliminary Results From a Multicenter International Study"
(Presentation 548) - Tuesday, May 17th at 2:45pm - 3:00pm, McCormick
Place - E450A

* "Capsule Endoscopy in Evaluation of Patients with Celiac Disease"
(Abstract M1322) - Monday, May 16th from 8am - 5pm, McCormick Place -
Hall E

Chronic Liver Disease

* "The Clinical Utility of Wireless Capsule Endoscopy in Patients with
Cirrhosis, Varices, and Anemia" (Abstract S1619) - Sunday, May 15th
from 8am - 5pm, McCormick Place - Hall E

Bleeding

* "Capsule Endoscopy for Acute Gastrointestinal Bleeding" (Presentation
SP674) - Tuesday, May 17th at 2:15pm, McCormick Place - E353AB

Small Bowel Tumors

* "Diagnosis and Outcome of Small Bowel Tumors Found by Capsule
Endoscopy: A Three Center Australian Experience" (Abstract M1309) --
Monday, May 16th from 8am - 5pm, McCormick Place - Hall E

* "Diagnostic Value of Video Capsule Endoscopy in Carcinoid Tumors"
(Abstract M1406) -- Monday, May 16th from 8am - 5pm, McCormick Place -
Hall E

* "Intestinal Tumors: Frequently Revealed by An Obscure Digestive
Bleeding (ODB) and More Easily Diagnosed by Capsule Endoscopy (VCE)"
(Abstract M1320) -- Monday, May 16th from 8am - 5pm, McCormick Place -
Hall E

Crohn's

* Videocapsule Endoscopy versus Colonoscopy for the Diagnosis of
PostSurgical Recurrence in Crohn's disease (CD): A pilot study
(Abstract M1307) -- Monday, May 16th from 8am - 5pm, McCormick Place -
Hall E

Additional Capsule Endoscopy Presentations

* "ASGE Poster Grand Rounds on Capsule Endoscopy" (Presentation SP313e).
Speakers include Drs. Robynne Chutkan and Blair Lewis - Monday, May
16th from 8:15am - 9:15am, McCormick Place - E353C

In addition, at DDW Given Imaging will commence the enrollment of sites for initial clinical trials of PillCam(TM) COLON. Similar to the PillCam SB and PillCam ESO, PillCam COLON is a naturally ingested, video capsule that will leverage the RAPID platform. On May 2nd, the Company announced its plans to submit the product for clearance by the U.S. Food and Drug Administration and launch it in Europe in 2006.

About Given Imaging

Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company is developing a complete line of PillCam(TM) video capsules for detecting disorders of the gastrointestinal tract. The company's technology platform is the Given® Diagnostic System, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient. The PillCam(TM) SB capsule is the only naturally ingested method for direct visualization of the entire small intestine. It is currently marketed in the United States and in more than 60 other countries and has benefited more than 200,000 patients worldwide. The PillCam(TM) ESO video capsule, which provides visual examination of the esophagus, has been cleared for marketing by the FDA. Additional capsules for visualization of the stomach and colon are under development. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel; it has direct sales and marketing operations in the United States, Germany and France, and local offices in Japan, Spain and Australia. For more information, visit http://www.givenimaging.com.

About Digestive Disease Week

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 14 - 19, 2005 in Chicago. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. Visit the Digestive Disease Week web site at http://www.ddw.org for additional information.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward- looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

--------------------------------------------------------------------------------
Source: Given Imaging